Guardian Pharmacy Services stock price target raised to $30 at Truist

Truist Securities raised its price target on Guardian Pharmacy Services (GRDN) to $30.00 from $28.00, maintaining a Buy rating, citing the company's strong market positioning, robust demand, and competitive technology infrastructure. This upgrade follows GRDN's Q2 2025 revenue growth of 15% to $344.3 million and EPS of $0.23, which met expectations, underscoring its continued growth trajectory. Despite the stock's significant 59% gain over the past year and current trading above its InvestingPro Fair Value, Truist's introduction of 2027 estimates signals confidence in GRDN's financial flexibility and organic expansion.

Analysis

Truist Securities has increased its price target for Guardian Pharmacy Services (GRDN) to $30.00 from $28.00, maintaining a Buy rating. The upgrade is underpinned by the company's strong market positioning, robust demand, and significant market share in its operating regions. This positive outlook is supported by strong financial performance, including an 18.5% revenue growth over the last twelve months and a 15% revenue increase to $344.3 million in the second quarter of 2025, with EPS of $0.23 meeting analyst expectations. Key competitive advantages cited include Guardian's technology infrastructure and the earnings potential from recently acquired facilities. While the stock has appreciated 59% over the past year and trades near its 52-week high, an InvestingPro analysis suggests its current price is above its Fair Value. Truist's introduction of 2027 estimates signals long-term confidence, reflecting the company's financial flexibility and a strategic focus on organic growth.

Key Decisions for Investors

• Investors may view the reaffirmed Buy rating and increased $30 price target from Truist as a positive signal, supported by consistent double-digit revenue growth and strong market positioning.
• Given the stock's 59% appreciation over the past year and its current valuation reportedly above its Fair Value, potential new investors should be cautious of the elevated entry point and assess if the growth outlook justifies the premium.
• Monitor future earnings reports for continued execution on organic growth and the successful integration of recently acquired facilities, which have been identified as a key driver of future earnings power.